妇科恶性肿瘤的免疫肿瘤学。

Immuno-oncology for Gynecologic Malignancies.

机构信息

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Adv Exp Med Biol. 2020;1244:149-182. doi: 10.1007/978-3-030-41008-7_7.

DOI:10.1007/978-3-030-41008-7_7

PMID:32301014

Abstract

Patients with advanced and/or recurrent gynecologic cancers derive limited benefit from currently available cytotoxic and targeted therapies. Successes of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to intense interest in clinical testing of these treatments in patients with gynecologic cancers. Currently, in the realm of gynecologic oncology, the FDA-approved use of immune checkpoint inhibitors is limited to microsatellite instable cancers and PD-L1-positive cervical cancer. However, there has been an exponential growth of clinical trials testing immunotherapy approaches, both alone and in combination with chemotherapy and/or targeted agents, in patients with gynecologic cancers. This chapter reviews some of the major reported and ongoing immunotherapy clinical trials in patients with endometrial, cervical, and epithelial ovarian cancer.

摘要

患有晚期和/或复发性妇科癌症的患者从当前可用的细胞毒性和靶向治疗中获益有限。免疫疗法在其他难以治疗的恶性肿瘤（如转移性黑色素瘤和晚期肺癌）中的成功应用，导致人们对在妇科癌症患者中进行这些治疗的临床测试产生了浓厚的兴趣。目前，在妇科肿瘤学领域，FDA 批准的免疫检查点抑制剂的用途仅限于微卫星不稳定癌症和 PD-L1 阳性宫颈癌。然而，已经有大量的临床试验测试免疫疗法方法，包括单独使用和与化疗和/或靶向药物联合使用，在妇科癌症患者中进行。本章回顾了一些主要报道的和正在进行的免疫疗法临床试验，涉及子宫内膜癌、宫颈癌和上皮性卵巢癌患者。